How do you ensure that every patient, regardless of their illness, receives the right treatment? For Robert Krams, founder of CureLogic, this is not a theoretical question but the core of his daily work to develop treatments using artificial intelligence that are fully tailored to the unique profile of every patient.
CureLogic hasn’t stood still since starting at unlock_. Robert specifically names the session with Pro Pharma as a turning point: ‘They explained in detail how the process from clinical trials to registration with the EMA works. That immediately gave us the tools to get started concretely.
Personalized medicine, powered by AI
CureLogic’s technology uses AI to select new medicines from its proprietary database of no less than 25 million molecules, based on personal biological data. This approach can be applied to virtually any disease, as long as the unique biological profile of the patient’s blood, tumor, or heart muscle tissue, for example, is known.
The idea originated from research into microRNAs, small molecules that play a key role in disease processes. ‘We discovered that microRNAs are promising, but in their original form often have side effects,’ Robert explains. ‘By adapting them step-by-step, we made them much more specific. This allowed us to develop millions of variants that work more precisely and cause fewer side effects. AI then helps us find exactly the right variant for the right patient.’
From scientific insight to innovation
It wasn’t a quick idea, but a process of years in which insights and experiments followed one another. When Robert and his team realized how many specific molecules they could create, the idea arose to use this knowledge for a personalized approach. With a smart architecture, they coupled molecule profiles to patient data, thus creating a completely new step in the development of personalized therapies.
A session with Pro Pharma immediately gave us the tools to get started concretely.
The added value of unlock_
CureLogic is now working on a financing strategy and is already in talks with the EMA to take the first steps towards clinical application. Thanks to the network and guidance from unlock_, Robert has a clear plan for the coming months.
advice for other founders
Robert gives other founders one clear tip: start applying for funding as early as possible. Grant application processes take a lot of time, often have low success rates, and only have a few rounds per year. He emphasizes:
“The sooner you start, the better your chances.”
Glimpse into the future
Robert looks ahead with a clear ambition. ‘In five years, I want us to have completed Phase 1 and Phase 2 studies and to actually be able to help patients. Our goal is simple: to develop a treatment that fits everyone,’ Robert says with a smile.
With AI, deep biological knowledge, and a healthy dose of perseverance, CureLogic is well on its way to making that dream a reality and permanently changing the way we think about medicine.